Effect and Safety of Travoprost 0.003% in Open Angle Glaucoma
10.3341/jkos.2021.62.4.531
- Author:
Su Min SUNG
1
;
Jong Heon KIM
;
Chong Eun LEE
;
Kyoo Won LEE
;
Sam SEO
Author Information
1. Cheil Eye Hospital, Daegu, Korea
- Publication Type:Original Article
- From:Journal of the Korean Ophthalmological Society
2021;62(4):531-537
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Purpose:To determine whether travoprost 0.003% has a similar intraocular pressure (IOP) reduction effect to that of travoprost 0.004% while reducing side effects.
Methods:This was a prospective study from January 2018 to December 2018 that included 102 patients diagnosed with open angle glaucoma who switched from travoprost 0.004% to travoprost 0.003%. We investigated the changes in IOP, conjunctival hyperemia, corneal erosion, and eyelid pigmentation before and at 3 months after switching to travoprost 0.003%. Additionally, a questionnaire survey of these patients was conducted to determine possible side effects, including hyperemia, stinging, pruritus, irritation, blurred vision, dryness, and foreign body sensation.
Results:IOP readings before and after switching to travoprost 0.003% were 12.95 ± 4.25 and 12.94 ± 3.89 mmHg, respectively, showing no significant change (p = 0.974). No changes were observed in corneal erosion or eyelid pigmentation; however, conjunctival hyperemia was reduced significantly from 1.60 ± 0.88 to 1.36 ± 0.84 (p = 0.001). No significant changes in hyperemia, stinging, pruritus, irritation, or foreign body sensation were reported; however, a significant improvement was noted for blurred vision and dryness (p = 0.008, p = 0.007, respectively).
Conclusions:We were able to show the effectiveness and safety of travoprost 0.003% as being as effective as travoprost 0.004% in reducing IOP and injections while improving blurred vision and dryness.
